Twist Bioscience Expands Gene Offering With Long Gene Fragments up to 5.0kb
08 Agosto 2024 - 7:00AM
Business Wire
Industry leading product available through
Twist ecommerce platform
Twist Gene Fragments now available up to 5.0kb
in length with the same speed, quality, and affordability as
shorter fragments
Turnaround time starting at two business
days
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today announced the expansion of
its DNA synthesis offering with the launch of Gene Fragments with
increased lengths ranging from 1.8kb to 5.0kb.
“Leveraging our Express Genes workflow, industry-leading error
rate and rapid turnaround times, we continue to push the boundaries
of what is possible in DNA synthesis to expand our portfolio of
products that enable our customers to quickly and efficiently
advance their research,” said Emily M. Leproust, Ph.D., CEO and
co-founder of Twist Bioscience. “Our goal is to serve all
researchers no matter where they are in their customer journey,
whether they are Makers, Buyers or transitioning from Makers to
Buyers. With the versatility, speed, high quality, scalability,
competitive pricing, and now increased length of Twist Gene
Fragments, we can further penetrate the Maker's Market and meet the
needs of customers who previously had to stitch together shorter
fragments, as well as enable customers working in RNA therapeutic
screening applications.”
Twist’s low error rate of 1:7,500 base pairs enables the
production of longer fragments that can be easily incorporated into
workflows, allowing researchers to select fewer colonies for
screening or to use the gene fragments directly in in vitro
transcription to make RNA. The increased length of the Gene
Fragment gives researchers the ability to further customize and
incorporate more elements into the fragment. Turnaround time for
all Gene Fragments starts at two business days, regardless of
length.
Twist Gene Fragments
Twist Gene Fragments are universally compatible with various
downstream cloning methods, allowing for seamless integration into
a wide array of applications. They can be utilized in protein
engineering, antibody discovery, pathway engineering, functional
genomics, diagnostic assays and other fields. Twist Gene Fragments
are customizable and have no order limit. Turnaround time for Gene
Fragments 0.3-5.0kb starts at two business days.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on LinkedIn | X | YouTube | Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including but not limited to, our ability to penetrate the
maker’s market, the compatibility of this product with downstream
cloning methods and integration into a wide array of applications.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period will
depend heavily on the success of our existing products and the
development and commercialization of additional products in the
synthetic biology, biologic drug and data storage industries; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Annual Report on Form 10-K
filed with the SEC on November 21, 2023 and subsequent filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Twist Bioscience
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240808863612/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Twist Bioscience (NASDAQ:TWST)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024